Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

A Multicenter, Phase 1/2, Open-Label Study Evaluating the Tolerability, Safety, Pharmacokinetics, and Efficacy of AMG 337 in Asian Subjects

NCT02096666 is registered in ClinicalTrials.gov with Amgen as lead sponsor.

NCT NCT02096666
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT02096666 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
A Multicenter, Phase 1/2, Open-Label Study Evaluating the Tolerability, Safety, Pharmacokinetics, and Efficacy of AMG 337 in Asian Subjects
Lead sponsor
Amgen
Phase
Phase 1/2
Overall status
Completed
Start date
April 15, 2014
Completion date
December 7, 2018
Enrollment
11 (actual)
Sites
4

Conditions

As the registry lists them; a condition with its own page is linked.

stomach neoplasms